What is the recommended treatment for pustular psoriasis?

Treatment of Pustular Psoriasis

For generalized pustular psoriasis (GPP), acitretin, cyclosporine, methotrexate, and infliximab are first-line therapies, with spesolimab (an IL-36 receptor inhibitor) now representing the only FDA-approved treatment specifically for GPP flares and chronic management. 1, 2

Treatment Algorithm by Disease Severity and Type

Generalized Pustular Psoriasis (GPP)

First-Line Therapies:

• Acitretin: Particularly effective for GPP with rapid response rates. One study showed 84% improvement in pustular psoriasis patients. Dosing ranges from 10-50 mg daily, with the key being to balance efficacy against tolerability. The response can be "quite rapid and remarkable" 1
• Cyclosporine: Effective but requires monitoring for renal function and hypertension. Contraindicated in patients with prior PUVA treatment, systemic malignancy (excluding non-melanoma skin cancer), or renal insufficiency 1
• Methotrexate: Standard systemic option 3
• Infliximab: Anti-TNF therapy with established efficacy 3

FDA-Approved Targeted Therapy:

• Spesolimab (IL-36 receptor inhibitor): The only medication with placebo-controlled randomized trial data for GPP. Approved in the USA, EU, Japan, China, and other countries for both acute flares (IV formulation) and chronic management (subcutaneous formulation) 2, 4

Second-Line Therapies:

• Adalimumab, etanercept, PUVA 3
• Ustekinumab (IL-12/23 inhibitor): Can be used for pustular psoriasis with limited evidence (Level C recommendation) 5
• IL-17 inhibitors (secukinumab, ixekizumab, brodalumab): Emerging evidence, particularly useful in patients who failed anti-TNF or anti-IL-12/23 agents 6

Palmoplantar Pustular Psoriasis

Preferred Approaches:

• Acitretin: Highly effective for hyperkeratotic palmoplantar disease, either as monotherapy or combined with phototherapy 1
• Ustekinumab: 67% clearance rate with 90 mg dose in patients >100 kg (Level B recommendation) 5
• Combination therapy: Acitretin plus NB-UVB or PUVA is more efficacious than monotherapy and allows lower cumulative doses of each agent 1

Combination Therapy Strategies

When monotherapy fails, evidence supports specific combinations:

Acitretin-Based Combinations:

• Start acitretin for 2 weeks, then add UVB phototherapy
• Reduce initial UVB dose by 30-50% in first week due to increased photosensitivity
• Acitretin 25 mg daily plus phototherapy equals acitretin 35 mg monotherapy in efficacy while reducing side effects 1

Biologic Combinations:

• Ustekinumab may be combined with acitretin, methotrexate, or NB-UVB to augment efficacy 5

Critical Considerations and Pitfalls

Avoid These Common Errors:

• Do not use cyclosporine in patients with prior PUVA treatment or uncontrolled hypertension 1
• Live vaccinations are contraindicated with cyclosporine 1
• When combining acitretin with phototherapy, failure to reduce initial UV dose by 30-50% risks severe erythema 1
• Acitretin is highly teratogenic; contraception requirements differ from other systemic agents

Special Populations:

• Pregnant women: Acitretin is absolutely contraindicated; cyclosporine requires caution. Treatment selection fundamentally changes 3
• Children: First-line agent selection differs from adults 3
• Elderly: Exercise caution with cyclosporine due to renal and cardiovascular risks 1

Evidence Quality and Emerging Data

The literature quality for pustular psoriasis treatment remains weak overall, with only 19% of publications reporting clinical trial results 2. Spesolimab represents a paradigm shift as the only agent with placebo-controlled randomized trial data specifically for GPP 2. The EFFISAYIL 2 study was the first randomized controlled trial to systematically evaluate continuous GPP management 4.

Traditional therapies (acitretin, cyclosporine, methotrexate, infliximab) are based primarily on case series and expert consensus rather than robust controlled trials 3. However, their decades of clinical use provide substantial real-world evidence for efficacy.

Treatment switching is common: Real-world Japanese data shows approximately one-third of GPP patients on biologics switch at least once, with a mean of 3.8 switches over 3.3 years 7. Key drivers for switching include lack of efficacy, loss of efficacy over time, side effects, and availability of more effective agents 7.

Monitoring Requirements

• Cyclosporine: Regular renal function tests, blood pressure monitoring, potential need for nephrologist consultation with prolonged use 1
• Acitretin: Lipid monitoring, liver function tests, pregnancy testing in women of childbearing potential
• Methotrexate: Complete blood count, liver function tests, renal function